This Austrian Biotech is Advancing Diagnostics for Age-related Diseases

While Vienna is better known for its opera house and delicious apfelstrudel, the city also boasts a number of successful biotechs. This week we had a look at TAmiRNA, a biotech developing new diagnostics for age-related diseases.

TAmiRNA-map

Mission: Founded in 2013, TAmiRNA is focusing on microRNAs, a class of small non-coding RNAs that play a major role in the regulation of gene-expression through base-pairing with complementary sequences within messenger RNAs (mRNAs). As microRNA expression is tightly regulated and often subject to change during the onset of disease, circulating microRNAs represent a promising new class of biomarkers. In 2016 the biotech launched the worldwide first miRNA-based kit for early detection of osteoporosis. In addition the company has developed a kit to measure new biomarkers of platelet function and cardiovascular diseases.

Comment: New biomarkers that detect the onset of age-related diseases such as osteoarthritis play a major role for early diagnosis and disease prevention. But as James Peyer, from Apollo Ventures, recently told us at our Labiotech Hangout, such biomarkers will also play a key role to conduct better preventative trials for drugs within the booming anti-aging pipeline. TAmiRNA also just entered a partnership the Swiss bioinformatics company SimplicityBio to identify additional diagnostic microRNAs in the field.

To learn more about microRNAs and their potential as diagnostic tools, have a look at TAmiRNA’s video below.


Images via shutterstock.com / RastoS Photographer
Images 

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.